VSTM Shows Promise
VSTM's VS-7375 demonstrates clinical activity with favorable safety in Phase 1/2 trial for KRAS G12D-mutated solid tumors
VSTM VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors